实用肿瘤学杂志 ›› 2013, Vol. 27 ›› Issue (5): 436-439.doi: 10.3969/j.issn.1002-3070.2013.05.013

• 综述 • 上一篇    下一篇

PLK1靶向治疗在非小细胞肺癌中的研究进展

任凤海综述,徐世东审校   

  1. 哈尔滨医科大学附属肿瘤医院胸外科(哈尔滨 150081)
  • 收稿日期:2013-02-15 出版日期:2013-10-28 发布日期:2013-10-15
  • 通讯作者: 徐世东,E-mail:shidongxu@yahoo.cn
  • 作者简介:任凤海,男,(1981-),硕士研究生,从事肺癌转移相关基因研究
  • 基金资助:
    国家自然科学基金资助项目(81172215)

New development of PLK1 targeted therapy in non-small cell lung cancer

REN Fenghai,XU Shidong   

  1. Depratment of Thoracic Surgery,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China
  • Received:2013-02-15 Online:2013-10-28 Published:2013-10-15

摘要: 世界范围内,非小细胞肺癌(Non-small cell lung cancer,NSCLC)是癌症死亡的主要原因。随着对NSCLC分子发病机制的深入了解,我们能够发现新的靶点和抗癌药物来治疗NSCLC。Polo样激酶-1(PLK1)是一种丝氨酸/苏氨酸激酶,并且是有丝分裂的关键性调节因子。PLK1抑制剂能够引起有丝分裂的停止并且引起肿瘤细胞凋亡。PLK1在肿瘤组织中过表达,然而在成熟组织中却很难检测到。RNA干扰(RNAi)是我们抗癌治疗的又一有力工具,它能够靶向mRNA并导致靶基因表达降低。在这篇综述中,我们将重点讨论与NSCLC相关的PLK1、PLK1抑制剂及靶向PLK1 的小干扰RNA(siRNA)。

Abstract: Worldwide,non-small cell lung cancer(NSCLC)is one of the leading causes of cancer-related death.With the development of the knowledge about the molecular pathogenesis underling NSCLC,we can find new targets and anticancer agents,and novel strategies of targeted therapys for the patients with NSCLC.The polo-like kinase1(PLK1)is a serine/threonine of kinase and it is a key regulator of mitosis.The inhibition of PLK1 can lead to mitotic arrest and tumor cell apoptosis.PLK1 is overexpressed in the tissue of tumor,however,it is hardly detected in most adult tissue.RNA interference(RNAi)is another powerful tool which can target mRNA and reduce the expression of the targeted gene.In this review,we will focus on the PLK1,and discuss the studies of PLK1 inhibitors and siRNA against PLK1,with special emphasises on NSCLC.

中图分类号: